Week In Review: HighlightLL Pharma Out-Licenses Parkinson's Treatment To Biohaven For $970 Million

HighlightLL Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven's Biohaven in a deal worth up to $970 million. Biohaven will have global rights to the product for $10 million upfront and $10 million in equity.